Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer

MET dysregulation is an oncogenic driver in non–small-cell lung cancer (NSCLC), as well as a mechanism of TKI (tyrosine kinase inhibitor) resistance in patients with epidermal growth factor receptor (EGFR)–mutated disease. This study was conducted to determine safety and preliminary efficacy of the...

Descripción completa

Detalles Bibliográficos
Autores principales: McCoach, Caroline E., Yu, Aiming, Gandara, David R., Riess, Jonathan W., Vang, Daniel P., Li, Tiahong, Lara, Primo N., Gubens, Matthew, Lara, Frances, Mack, Philip C., Beckett, Laurel A., Kelly, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140807/
https://www.ncbi.nlm.nih.gov/pubmed/34036220
http://dx.doi.org/10.1200/PO.20.00279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140807/
https://www.ncbi.nlm.nih.gov/pubmed/34036220
http://dx.doi.org/10.1200/PO.20.00279

Ejemplares similares